A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability and Efficacy of ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
收藏DataCite Commons2025-03-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007701/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the run-in phase of this study is to determine the appropriate and tolerable
dose of ZD6474 (200mg or 300mg) to be administered in combination with paclitaxel and
carboplatin in subjects with previously untreated locally advanced or metastatic NSCLC. This
phase of the trial is closed to enrollment.
The purpose of the randomized phase of this study is to determine the efficacy of ZD6474
alone versus that of ZD6474 in combination with paclitaxel and carboplatin versus that of
paclitaxel and carboplatin alone in subjects with previously untreated locally advanced or
metastatic NSCLC. This phase of the trial is closed to enrollment.
提供机构：
Vivli
创建时间：
2022-02-10
